Background Infliximab, an anti-TNF-α monoclonal antibody, administered to Behçet's disease (BD) patients in Japan with refractory intraocular inflammation, has shown excellent clinical results. However, some patients demonstrate a decreased response to infliximab during the course of the treatment. In the present study, we investigated the correlation between this reduced therapeutic effect and elevation of the serum antinuclear antibody (ANA) titers in patients with BD who were undergoing infliximab therapy. Methods Seventeen patients (14 males and three females) with uveitis in BD who were undergoing treatment with infliximab for 2 years or longer were enrolled. Their blood test results and clinical histories were obtained from medical records. Results One patient (5.9%) was ANA-positive prior to the initiation of infliximab, and 11 patients (64.7%) developed positive ANA during the therapy. The appearance of ANA was observed 6 months after the initiation of the infliximab therapy, and its titers gradually increased. None of the patients showed lupus symptoms. Five patients (29.4%) have suffered from ocular inflammatory attacks since the sixth month from the initiation of infliximab treatment and all of them were ANA-positive. In contrast, four patients (23.5%) who were ANA-negative experienced no ocular attacks during the follow-up period. Conclusions Here we report the positive conversion and subsequent elevation of serum ANA titers in some patients with BD after the initiation of infliximab therapy. Since all recurrences of uveitis were shown only in the ANA-positive patients, serum ANA titer may be a helpful biomarker for predicting the recurrence of ocular attacks in BD patients treated with anti-TNF-α antibody therapies.
Introduction
Behçet's disease (BD) is a chronic systemic inflammatory disease characterized by recurrent oral aphthous ulcers, genital ulcers, skin lesions, gastrointestinal involvement, vasculitis, neurological manifestations, and intraocular inflammation. BD is one of the major etiologies of endogenous uveitis in Japan [1] , however, its prevalence and clinical features vary among countries and ethnic groups [2, 3] . Recurrent episodes of inflammatory ocular attacks can cause severe visual loss. To prevent the relapse of intraocular inflammation, colchicine and various immunosuppressive agents are administered including cyclosporine A (CyA), which is a selective immunosuppressive agent of T-lymphocytes. However, some patients cannot use these drugs due to intolerable side-effects. Moreover, some patient's diseases are refractory to these agents and can progress to vision loss [4] [5] [6] .
Infliximab (IFX) is a chimeric monoclonal antibody to TNF-α that can minimize the immunological response when used in humans [7] . It neutralizes both membrane-binding and soluble TNF-α, in addition to suppressing TNF-α production by macrophages. IFX is commonly administered to patients with rheumatoid arthritis [8, 9] , Crohn's disease [10] , psoriasis [11, 12] , and in case of refractory uveitis with non-infectious etiologies including BD [13] [14] [15] [16] [17] [18] [19] [20] . IFX is effective for preventing relapse of intraocular inflammations in BD and its efficacy has been well documented in previous studies [13] [14] [15] [16] [17] [18] [19] . In Japan, IFX was approved for use in BD patients with refractory uveoretinitis by the Ministry of Health, Labour and Welfare, Japan in January 2007 based on the excellent results from multicenter clinical trials [15, 21] . Though IFX is an excellent agent in the treatment of the BD with refractory uveoretinitis, it has been observed to have decreased efficacy in a subset of BD patients with uveoretinitis [19] . One report showed the development of autoantibodies including antinuclear antibody (ANA) during IFX treatment in BD [22] , however, the mechanisms and the meanings of it remain unknown.
In the present study, we investigated ANA titers of the BD patients receiving IFX therapy and examined the correlation between the elevation of ANA and the therapeutic efficacy.
Materials and methods
BD patients with refractory uveoretinitis who had been administered IFX for 2 years or longer were enrolled at Hokkaido University Hospital. The results of their blood tests and clinical histories were obtained from medical records. BD was diagnosed based on the criteria set by the BD Research Committee of Japan, which is part of the Ministry of Health, Labour and Welfare, Japan [23] . The level of ocular inflammation was graded by means of the Standardization of Uveitis Nomenclature (SUN) grading criteria [24] . When a patient showed more than two steps of increase in level of inflammation or increase from grade 3+ to 4+, it was considered an inflammatory ocular attack. Ocular attacks of BD flare up repeatedly and usually disappear within a few weeks. Each ocular attack shows a varying degree of uveitis including only mild iridocyclitis or severe obstructive retinal vasculitis with retinal exudates. The number of ocular attacks was counted regardless of the severity and added both eyes.
Patients were administered 5 mg/kg of IFX intravenously at weeks 0, 2, and 6 as the initial series of infusions and thereafter every 8 weeks. Serum ANA and anti-doublestranded DNA (dsDNA) antibodies were examined prior to IFX infusion. ANA titers were quantified using an indirect immunofluorescence technique using human epithelial (Hep2) cells. Results were classified as positive (ANA≥80) or negative (ANA≤40) according to previous reports [25] [26] [27] [28] [29] [30] [31] . Anti-dsDNA antibodies were identified using enzyme-linked immunosorbent assay (ELISA).
Statistical analyses were performed using the MannWhitney U test; p values <0.05 were considered to be statistically significant. This study followed the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Hokkaido University Hospital.
Results
The demographics and clinical characteristics of the 17 Japanese patients, i.e., 14 (82.4%) males and three (17.6%) females ranging in age from 15 to 58 (mean age: 36.9) years, enrolled in the study are listed in Table 1 . The rate of ocular inflammatory attacks during 6 months prior to the initiation of IFX was 3.8±2.1 (mean±SD). IFX therapy significantly reduced the rate of ocular attacks to 0.7±1.1 during the first 6 months after the initiation of IFX (p<0.01). Best-corrected visual acuities (BCVA) were reported 1 year after the initiation of IFX; IFX therapy had successfully maintained their vision acuity (Fig. 1) .
ANA profiles and the frequency of ocular attacks in BD patients treated with IFX are shown in Table 2 . One patient (5.9%) was ANA-positive prior to the initiation of IFX. Anti-dsDNA antibodies were never detected prior to IFX induction. The change in ANA-positive rates is shown in Fig. 2 . The positive conversion of ANA became common 6 months after the initiation of IFX, and the positive titers continued to increase. At the end of the follow-up period, 13 patients (76.4%) were identified positive for ANA (Fig. 2) . One patient (5.9%) developed anti-dsDNA antibodies (case #14). However, none of the patients showed lupus symptoms.
The correlation of ocular attacks with elevation of ANA titer is shown in Fig. 3 . At the 6th month after the IFX induction, five patients (29.4%) were ANA-positive and 12 (70.6%) were negative. In the ANA-positive group, three patients (60%) had ocular inflammatory attacks during the first 6 months after IFX administrations, whereas in the ANA-negative group, four (33.3%) patients had these attacks. Ocular attacks were much milder than those before IFX therapy both in the ANA-negative group and ANApositive group.
However, since the 6th month of IFX therapy, all of five patients (29.4%) suffering from a relapse of ocular inflammatory attacks were ANA-positive, and three of five patients had multiple ocular attacks. In two of these three patients, the administration interval was shortened from 8 to 7 weeks, and this successfully led to a lower rate of the ocular attacks. On the other hand, all of four patients (23.5%) with negative ANA had no ocular attacks.
Discussion
ANA appeared in the sera of BD patients 6 months after IFX induction, and its titer gradually increased. It was reported that the development of ANA and anti-dsDNA antibodies is seen during the course of anti-TNF-α therapy in patients with some autoimmune diseases such as rheumatoid arthritis [32] [33] [34] , psoriasis [35] , Crohn's disease [36] , and BD [22] . In the present study, 75.0% of the patients converted to ANA-positive during the course of IFX therapy and positive ANA titers (1:80) had been detected in one patient on study enrolment. This patient experienced a twofold increase in Before IFX administration After IFX administration LogMAR Fig. 1 Visual acuity before and after initiation of IFX. Best-corrected visual acuities (BCVA) 1 year after the initiation of IFX. IFX therapy successfully maintained the visual acuity in these patients the titer (1:160). Only one patient (5.9%) converted to anti-dsDNA antibody-positive during the follow-up period. These findings are consistent with previous studies of other autoimmune rheumatoid diseases, which reported that 25-71% and 4-46% patients became positive for ANA and anti-dsDNA antibodies after IFX initiation in case of psoriasis and rheumatoid arthritis [32, 37, 38] . In these previous studies, a small number of patients had lupus-like symptoms [39] [40] [41] . Suhler EB et al. also reported the results of a prospective study in which 23 patients with non-infectious uveoretinitis including four of BD patients were enrolled [42] . In the report, ANA titers developed in 15 (75.0%) of the 20 patients and two patients with very high titer showed arthritis. Although none of the patients in our study have shown lupus symptoms, we have to observe the patients very carefully.
It is still unknown how ANA and anti-dsDNA antibodies develop during IFX therapy. One possible explanation is that TNF-α may up-regulate cellular expression of the adhesion molecule CD44, which plays a role in the clearance of apoptotic neutrophils by phagocytes [43, 44] . Impaired clearance of apoptotic cells and reduced CD44 expression on leukocytes has been reported in systemic lupus erythematosus (SLE) [45, 46] . IFX may down-regulate CD44 expression and induce an immune reaction toward their own nuclei by impairment of the clearance of apoptotic cells.
In the present study, we also demonstrated the association between the development of ANA and reduced effects of IFX therapy in BD patients. Only a few studies have reported the association of serum ANA development with the effects of IFX [35, 42] . Pink et al. reported that ANA titer was associated with the loss of response to anti-TNF-α therapy in psoriasis. In our study, during 6 months after the initiation of IFX therapy, several patients experienced mild ocular inflammatory attacks, both in the ANA-positive and ANA-negative groups. Presumably, it takes some time for IFX to exert an inhibitory effect on severe ocular inflammation in BD patients. However, after the 6th month IFX therapy, the cases suffering from the relapse of ocular inflammatory attacks were limited to ANA-positive patients. Similar to the study in psoriasis [35] , these results suggest that the development of elevated levels of serum ANA may be associated with the reduction of IFX efficacy for BD patients. Suhler EB et al. mentioned no clear relation between the development of ANAs and ocular therapeutic response [42] . The subjects in the report included a variety of uveitis cases, in contrast to our study, which targeted only BD. The tight disease enrollment may be the reason why we could show the relation between recurrences of uveitis and high titer of ANA.
The exact association between ANA and IFX also remains unknown. It has also been found that repeated infusion of IFX leads to induction of antibodies to IFX (ATI) that reduce the efficacy of IFX. This phenomenon has been a serious issue in rheumatoid arthritis [47] , Crohn's disease [48] , psoriasis [49, 50] and BD [51] therapy. ANA and ATI, both of which appear during the course of IFX treatment, are likely to be involved in the reduced efficacy of IFX; however, the correlation between the two antibodies remains to be elucidated. We speculate that repeated administration of protein agents such as IFX may activate a systemic immune response, leading to the production of various autoantibodies including ANA and ATI. Therefore, detection of high titer of ANA indicates the development of ATI in the patients. According to this theory, the patients, such as cases #6 and #7, with high ANA titer (640×) may have already had ATI. These patients should be monitored closely for further symptoms. If the theory is confirmed that ATI is strongly correlated with the decreased therapeutic efficacy of IFX, we need to consider concomitant use of immune modulatory medicine in BD.
IFX has provided a new way to maintain good vision for a long time in many BD patients with severe uveitis. However, in certain cases IFX becomes less effective while longterm use of IFX. Serum ANA titers may be one of the helpful biomarker to predict IFX ineffectiveness.
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